To see this content from Vimeo, you must give your consent to allow cookies from Vimeo to be stored on your device.

Alexander Eggermont presents the results of KEYNOTE-054

Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, talks about the key findings of the KEYNOTE-054 trial and highlights pembrolizumab’s high therapeutic index.